European School of Oncology

Last updated

The European School of Oncology (ESO) is a provider of continuing medical education to oncology professionals, with a particular focus on areas of Central and Eastern Europe and the Balkans region. [1] [2]

Contents

It is a non-profit organisation, based in Milan, Italy, that is independently funded via two foundations ‒ the ESO Foundation (ESOF) and the Fondazione per la Formazione Oncologica (FFO), primarily through a legacy left to the School by the last surviving members of the family Necchi-Campiglio. [3]

History

The School was founded in 1982 by Umberto Veronesi, an Italian breast surgeon and Scientific Director of the National Cancer Institute of Milan. The concept, first outlined at the 1981 founding congress of the European Society of Surgical Oncology, was for a permanent interdisciplinary and international school, free from non-medical influence, and in line with the medical traditions of the ‘Old Continent’ of Europe, which were seen as distinct from the medical culture in the US, in putting a greater emphasis on the therapeutic importance of the doctor‒patient relationship. [4]

The founding scientific leadership of the School was drawn from a range of oncology disciplines and European countries. [5] [6] They included Michael Peckham, a UK-based radiotherapist and co-founder of the European Society for Therapeutic Radiology and Oncology (now European Society for Radiotherapy and Oncology),; [7] Herbert Pinedo, a leader in the emerging specialism of medical oncology, based in the Netherlands, and author of early editions of Cancer Chemotherapy; [8] Franco Cavalli, a Swiss haematologist and founding member of the European Society for Medical Oncology, Louis Denis, a urologist and founder member of the European Organisation for Research and Treatment of Cancer genito-urinary group; [9] and Umberto Veronesi himself, an Italian breast surgeon, who had developed and trialled the quadrantectomy technique for breast conserving surgery [10] and initiated the first trials investigating the impact of adjuvant chemotherapy in operable breast cancer. [11]

Multiprofessional cancer care education

The first ESO oncology course was held in 1982 in the Castello di Pomerio in Lombardy northern Italy, near Milan. [4] [5] The teaching faculty comprised most of the School's founders, and the course covered the principles of management of the main cancers from a multidisciplinary standpoint. In its early years the School concentrated on post-graduate courses in medical oncology, which at that time was treated in most of Europe as a branch of internal medicine, rather than a specialism requiring its own curriculum and qualifications. [12] From 2001, the School began to focus much of its work on countries in Central and Eastern Europe and the Balkans region, where survival rates for cancer were markedly lower than in Western Europe and Northern Europe. [2] [13] It also started to widen its areas of work to support oncologists at different stages in their careers, starting from the time they leave medical school. In 2002 ESO ran the first five-day Masterclass in Clinical Oncology. [14] [15] In 2004 it initiated a summertime Oncology for Medical Students course. [16] [17] In 2008 the e-ESO distance learning programme was started, to increase global access to oncology education. [18] In 2012 ESO launched a visiting professors programme, primarily to support clinical institutes in Eastern Europe and the Balkan Region. [2] In 2013 it added a scheme for clinical training fellowships at centres of excellence across Europe, [19] and also set up certificates of competence as specialist qualifications in lymphoma, [20] breast cancer, [21] and gastrointestinal cancer, [22] and a certificate of advanced studies in lung cancer, [23] which run in collaboration with the University of Ulm, the University of Zurich and the Università della Svizzera italiana. In 2020 the School set up the ESO college ESCO, [24] to bring all these different initiatives into a structure that alumni can pursue step by step.

Societies

ESO is a member of the Union for International Cancer Control and the European Cancer Organisation.

Journal

The ESO official journal is Critical Reviews in Oncology/Hematology, which publishes critical reviews in all fields of oncology and hematology, as well as reviews and original research in the field of geriatric oncology.

Related Research Articles

Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis by the same mechanism as rHuEpo and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Darbepoetin is marketed by Amgen under the trade name Aranesp.

<span class="mw-page-title-main">Oncology nursing</span>

An oncology nurse is a specialized nurse who cares for cancer patients. These nurses require advanced certifications and clinical experiences in oncology further than the typical baccalaureate nursing program provides. Oncology nursing care can be defined as meeting the various needs of oncology patients during the time of their disease including appropriate screenings and other preventive practices, symptom management, care to retain as much normal functioning as possible, and supportive measures upon end of life.

<span class="mw-page-title-main">Chandler Park</span> American physician

Chandler Park is an American physician, medical journalist, and clinical researcher. In June 2021, his cancer research was published in prominent medical journals including the New England Journal of Medicine and Journal of Clinical Oncology. Park also contributes regularly as an expert physician for popular newspapers and magazines such as Newsweek, Reader's Digest, U.S. News & World Report, The Exponent-Telegram, College of St. Scholastica, and Medscape and writes medical news for Doximity.

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via cytotoxicity.

<span class="mw-page-title-main">Sentinel lymph node</span> First lymph node to receive drainage from a primary tumor

The sentinel lymph node is the hypothetical first lymph node or group of nodes draining a cancer. In case of established cancerous dissemination it is postulated that the sentinel lymph nodes are the target organs primarily reached by metastasizing cancer cells from the tumor.

The European Institute of Oncology is a non-profit private-law comprehensive cancer centre located in Milan, Italy. It is a clinic, a research centre and a training institution. IEO is a member of EU-LIFE, an alliance of leading life science research centres in Europe.

<span class="mw-page-title-main">V. Craig Jordan</span> American/British pharmacologist (born 1947)

Virgil Craig Jordan,, is a scientist with American and British citizenship specializing in drugs for breast cancer treatment and prevention. Currently, he is Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer.

<span class="mw-page-title-main">Umberto Veronesi</span> Italian oncologist, physician, scientist, and politician (1925–2016)

Umberto Veronesi was an Italian oncologist, physician, scientist and politician, internationally known for his contributions on prevention and treatment of breast cancer throughout a career spanning over fifty years.

<span class="mw-page-title-main">Pertuzumab</span> Pharmaceutical drug

Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.

<span class="mw-page-title-main">Fenretinide</span> Chemical compound

Fenretinide (N-(4-hydroxyphenyl)retinamide; 4-HPR) (INN) is a synthetic retinoid derivative. Retinoids are substances related to vitamin A. It has been investigated for potential use in the treatment of cancer, as well as in the treatment of cystic fibrosis, rheumatoid arthritis, acne, psoriasis, and has been found to also slow the production and accumulation of a toxin that leads to vision loss in Stargardt's patients.

<span class="mw-page-title-main">Breast-conserving surgery</span> Surgical operation

Breast-conserving surgery refers to an operation that aims to remove breast cancer while avoiding a mastectomy. Different forms of this operation include: lumpectomy (tylectomy), wide local excision, segmental resection, and quadrantectomy. Breast-conserving surgery has been increasingly accepted as an alternative to mastectomy in specific patients, as it provides tumor removal while maintaining an acceptable cosmetic outcome. This page reviews the history of this operation, important considerations in decision making and patient selection, and the emerging field of oncoplastic breast conservation surgery.

<span class="mw-page-title-main">Gordon McVie</span> British oncologist and cancer researcher (1945–2021)

John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.

Martine J. Piccart-Gebhart is a Belgian medical oncologist. She is a professor of oncology at the Université Libre de Bruxelles and scientific director at the Jules Bordet Institute in Brussels, Belgium. She is also a member of the Belgian Royal Academy of Medicine.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

Europa Donna – The European Breast Cancer Coalition is an independent non-profit organisation whose members are affiliated groups from 47 countries throughout Europe. The organisation was set up by a group of women from various European countries in 1994. Its head office is in Milan, Italy.

Kathleen I. Pritchard, is the head of oncology at Sunnybrook Health Sciences Centre in Toronto, Canada, specializing in breast cancer therapies, and leading the clinical trials division of the centre. She has authored numerous studies on women's health, breast cancer, hormone replacement therapy, public health, and research methodology. According to Thomson Reuters, Pritchard was one of the most cited researchers in the world in 2014 and 2015.

Professor Dame Lesley Jean Fallowfield DBE is a British cancer psychologist and a professor of psycho-oncology at the University of Sussex. The main outcomes of her research have been the establishment of assessment tools to measure quality of life in clinical trials of cancer patients and the design of educational programmes to improve oncologists' communication with their patients.

Bruce Allan Chabner is an American medical researcher who worked at the National Cancer Institute and now is a professor of medicine at Harvard Medical School. He is also the director of clinical research at the Cancer Center at Massachusetts General Hospital. His research focuses on anti-folate drugs for the treatment of cancer. His work at NIH led to the development of Taxol, a commonly prescribed breast cancer drug.

<span class="mw-page-title-main">Giovanni Corso</span> Italian academic and surgeon

Giovanni Corso is an Italian academic and surgeon. He is a Senior Researcher at University of Milan. Corso is the current president of the European Cancer Prevention Organization and the editor-in-chief of the European Journal of Cancer Prevention. His main research activities are on hereditary diffuse gastric cancer and hereditary lobular breast cancer associated with Cadherins disfunction.

References

  1. ↑ Ernberg, Ingemar (March 2, 2019). "Education aimed at increasing international collaboration and decreasing inequalities". Molecular Oncology. 13 (3): 648–652. doi:10.1002/1878-0261.12460. PMC   6396351 . PMID   30677237.
  2. 1 2 3 "Eniu, Alexandru et al. (2019) Challenging cancer inequalities within Europe through education and training: ESO's vision. Cancer Control 75" (PDF).
  3. ↑ "Sorelle Nedda e Gigina Necchi". November 6, 2017.
  4. 1 2 Apollonio U (ed) (1992) A Decade of Cancer Education and Training in Europe. Milan, Arnoldo Mondadori Editore
  5. 1 2 Wagstaff Anna with Costa Alberto (2012) Learning to Care ESO at 30, European School of Oncology, Milan
  6. ↑ Veronesi Umberto with Costa Alberto (2009) L’uomo dal camice bianco. Rizzoli, Milan
  7. ↑ "History".
  8. ↑ Pinedo, Herbert (1979) Cancer Chemotherapy. Elsevier Science Publishing Company BV. ISBN   9780444900845
  9. ↑ "In memoriam: Prof. Dr. Louis Denis (1933-2021) - Uroweb". Uroweb - European Association of Urology.
  10. ↑ Veronesi, Umberto; Saccozzi, Roberto; Del Vecchio, Marcella; Banfi, Alberto; Clemente, Claudio; De Lena, Mario; Gallus, Giuseppe; Greco, Marco; Luini, Alberto; Marubini, Ettore; Muscolino, Giuseppe; Rilke, Franco; Salvadori, Bruno; Zecchini, Annamaria; Zucali, Roberto (January 13, 2010). "Comparing Radical Mastectomy with Quadrantectomy, Axillary Dissection, and Radiotherapy in Patients with Small Cancers of the Breast". New England Journal of Medicine. 305 (1): 6–11. doi:10.1056/NEJM198107023050102. PMID   7015141.
  11. ↑ Bonadonna, Gianni; Brusamolino, Ercole; Valagussa, Pinuccia; Rossi, Anna; Brugnatelli, Luisa; Brambilla, Cristina; De Lena, Mario; Tancini, Gabriele; Bajetta, Emilio; Musumeci, Renato; Veronesi, Umberto (February 19, 1976). "Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer". New England Journal of Medicine. 294 (8): 405–410. doi:10.1056/NEJM197602192940801. PMID   1246307 – via Taylor and Francis+NEJM.
  12. ↑ "Recognition and Status of Medical Oncology". www.esmo.org.
  13. ↑ "Znaor A, van den Hurk C, Primic-Zakelj M, et al. (2013) Cancer incidence and mortality patterns in South Eastern Europe in the last decade: Gaps persist compared with the rest of Europe. Eur J Cancer 49:1683–1691".
  14. ↑ Pavlidis, Nicholas; Peccatori, Fedro; Aapro, Matti; Eniu, Alexandru; Stahel, Rolf; Cervantes, Andres; Cavalli, Franco; Costa, Alberto (June 1, 2021). "ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test". Journal of Cancer Education. 36 (3): 556–560. doi:10.1007/s13187-019-01664-6. PMID   31845109. S2CID   209381347 – via Springer Link.
  15. ↑ Pavlidis, Nicholas; Peccatori, Fedro A.; Aapro, Matti; Eniu, Alex; Kay, Stanley; Rolfo, Christian; Cavalli, Franco; Costa, Alberto (July 1, 2020). "The impact of the European School of Oncology masterclass in clinical oncology on self-professional development". Critical Reviews in Oncology/Hematology. 151: 102976. doi:10.1016/j.critrevonc.2020.102976. PMID   32389896. S2CID   218584575 – via ScienceDirect.
  16. ↑ "Pavlidis, Nicholas et al. (2007) Oncology for Medical Students: an ESO contribution to undergraduate cancer education. Cancer Treat Rev 33(5):419‒426".
  17. ↑ Pavlidis, Nicholas; et al. (January 2, 2021). "ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students: 4 Years of Experience (2016–2019)". Journal of Cancer Education. 37 (4): 1239–1244. doi:10.1007/s13187-020-01947-3. PMID   33387267. S2CID   256074346 – via Springer Link.
  18. ↑ "ESO - European School of Oncology". www.e-eso.net.
  19. ↑ Pavlidis, Nicholas; Peccatori, Fedro A; Aapro, Matti; Eniu, Alex; Cavalli, Franco; Costa, Alberto (September 1, 2020). "The clinical training centers fellowships: a European School of Oncology career development program (2013–2019)". Future Oncology. 16 (26): 1969–1976. doi:10.2217/fon-2020-0193. PMID   32567377. S2CID   219972212 – via futuremedicine.com (Atypon).
  20. ↑ "Certificate of Competence - Universität Ulm". www.uni-ulm.de.
  21. ↑ Montagna, Giacomo; Anderson, David; Bochenek-Cibor, Justyna; Bozovic-Spasojevic, Ivana; Campos, Conceicao; Cavallero, Sandro; Durutovic, Ivana; Gomez Cuadra, Manuel Oscar; Irfan, Tazia; Joly, Laetita; Kassem, Loay; Kolben, Theresa M.; Machacek, Martina; Mir Khan, Benazir; Nagvekar, Mayur; Pellegrino, Benedetta; Pogoda, Katarzyna; Câmara, Gabriela Rodrigues; Ferreira, Pedro Santos; Seferi, Melsi; Talibova, Narmin; Van den Rul, Nathalie; Vettus, Elen; Rocco, Nicola (February 2, 2019). "How to become a breast cancer specialist in 2018: The point of view of the second cohort of the Certificate of Competence in Breast Cancer (CCB2)". The Breast. 43: 18–21. doi:10.1016/j.breast.2018.10.006. PMID   30388502. S2CID   53216867.
  22. ↑ "Certificate of Advanced Studies in Gastrointestinal Cancer (CAS-GI)".
  23. ↑ "CAS in Lung Cancer".
  24. ↑ "About ESCO".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.